The augmentation of local anesthetics with various adjuvants to enhance the quality and efficacy of subarachnoid block is clinically in practice since long. Comparative studies on effects of adding intrathecal tramadol and buprenorphine has never been studied before. Both drygs are esily available in our country. So, we conducted this study to evaluate and compare the characteristics of subarachnoid blockade, duration of postoperative analgesia, dose of recue analgesic postoperatively, and adverse effects of intrathecal buprenorphine (50 µg) and intrathecal tramadol (30 mg) as adjuvants to 0.5% hyperbaric bupivacaine for lower abdominal surgeries Methodology: This prospective randomized, single blind controlled trial was carried out at Services Hospital Lahore, from January to July 2018. 110 American society of Anesthesiologist I -II male patients, 35 to 45 y of age undergoing subarachnoid block for infra-umbilical surgery were randomized into two groups. Group T (n = 55) patients received 10 mg of 0.5% bupivacaine and 30 mg of tramadol intrathecally, while group B (n = 55) received 10 mg 0.5% bupivacaine with 50 µg of buprenorphine. Sensory testing was done by pin prick method using 25G blunt needle and time taken to reach T10 level noted. Motor block was assessed using Modified Bromage Scale. The time taken to reach modified Bromage 3 was recorded. Side effects and postoperative analgesia noted for 24 h by VAS score every 20 min for first 2 h in PACU and then 4 hourly for 24 h in the ward. Patients with inadequate block were converted into general anesthesia and were excluded from the study. Time to first rescue analgesia, and total analgesic required in 24 h were compared in two groups.
INTRODUCTION
Subarachnoid block is one of the most widely practiced and effective regional approach for elective and emergency cesarean sections, lower abdominal surgeries, lower limb orthopedic and urological procedures. 1 it has earned its high popularity due to low cost, awake patient, prompt onset, and rapid recovery and no need of airway manipulation. 2 The duration of postoperative analgesia can be prolonged by adding a small dose of opioid as adjunct with local anesthetic solution in intrathecal space. Intrathecal opiates function synergistically with local anesthetics and augment their sensory block without impacting the sympathetic activity. 3 Opioids act by activation of opioid receptors in the dorsal gray matter of spinal cord, which modifies the function of afferent pain fibers. 4 The use of opioids through other routes has been associated with high frequency of undesirable side effects, including respiratory depression, sedation, hypotension, bradycardia, nausea, and vomiting. 5 American Society of Anesthesiologists (ASA) recommends neuraxial opioids over parenteral opioids for postoperative analgesia after neuraxial blocks. 6 Buprenorphine is a long-acting, lipid soluble, mixed agonist-antagonist opioid. 3 It is known to increase duration of analgesia at least by 12-15 h, without causing any significant fall in BP or pulse rate when used intrathecally. 7 Tramadol is not a centrally acting opioid analgesic and it has very less respiratory depressant effecr due to its 6000-fold less affinity for µ-receptors in contrast to morphine. It also discourages serotonin and norepinephrine reuptake in the spinal cord and has no revealed neural toxicity. 8 It's low cost, easy availability and its ability to extend the span of sensory block, motor block, and postoperative analgesia make it an attractive adjuvant to spinal anesthesia. 9 Not much published work is available comparing analgesic properties of intrathecal buprenorphine to other narcotics such as tramadol. Hence, we conducted this prospective, randomized control trial to evaluate and compare the characteristics of subarachnoid block, postoperative analgesia and sideeffects with the addition of buprenorphine (50 µg) or tramadol (30 mg) to 0.5% hyperbaric bupivacaine in infra-umbilical surgeries.
METHODOLOGY
After approval from institutional ethical review committee, this prospective, randomized, single blind control study was conducted at Department of Anesthesiology, Services Hospital Lahore. Sample size was calculated using WHO statistical software SSIZE, based upon hypothesis test for difference of two means. At significance level of alpha 5% and power of study 80%, estimated sample size was 55 for each group. Sampling technique used was nonprobability convenience. Patients aged 18-60 y of either sex, belonging to ASA Physical Status I and II, scheduled for elective hernia repair, requiring sub arachnoid block were included in the study. Patients who were taking α2-adrenergic agonist or antagonist therapy, patients who were having labile hypertension, uncontrolled cardiac disease, heart block/dysrhythmia, autoimmune disorders, communication difficulties, e.g. mental retardation or deafness and allergy to the drug or local anesthetics were excluded from study. The enrolled patients were randomized by computer generated random number sequence and blind envelop technique into two groups; Group B and Group T, each comprising of 55 patients. Group B received 2 ml of 0.5 % of hyperbaric bupivacaine and 1 ml of 50 µg buprenorphine (0.3 mg diluted in 6 ml normal saline). Group T received 2 ml of 0.5% hyperbaric bupivacaine and 1 ml of 30 mg tramadol (100 mg diluted in 3.2 ml normal saline). Total drug volume used was 3 ml in both groups.
On arrival to the operating room, IV access was secured and patients preloaded with 10 ml/kg of crystalloid solution over 15 min. The baseline systolic and diastolic blood pressures, heart rate and oxygen saturation were recorded.
After all aseptic measures subarachnoid block was performed and the study drug was injected along with bupivacaine at L3-L4 interspace, over 10-15 sec. The time of injection completion was considered zero time for the study and all measurements were recorded from this point.
Following the block, patients were made to lie supine. Time taken to reach sensory block till t10 and motor block till modified bromage scale 3 was recorded. Sensory testing was done by pin prick method using 25G hypodermic blunt needle and time taken to reach T10 level noted down. Patients did not receive any additional analgesic in intraoperative period while anxious patients received intravenous midazolam 1 mg. The incidence of any adverse effects such as hypotension, bradycardia, shivering, nausea, vomiting, pruritus, respiratory depression or ECG changes were noted. Hypotension was defined as a fall in systolic blood pressure by 30% from baseline. Bradycardia was defined as a heart rate less than 50 beats per min. From zero min till demand of first rescue analgesia by the patient was defined as postop analgesia. Hypotension and bradycardia was treated with fluid bolus, phenylephrine 50 µg aliquots and atropine 0.6 mg respectively. Post-operatively the hemodynamic variables and oxygen saturation were recorded in the PACU until complete recovery of the patients from anesthesia.
Postoperatively, pain was assessed using VAS every 15 min during first 2 h and then regularly at an interval of 4 h till the next 24 h in the ward. Whenever VAS score reached > 4, rescue analgesia was given in the form of inj tramadol 1 mg ̷ kg IV. Time to the first dose of tramadol and the total dose required during first 24 h was recorded.
After completion of the study, the results were compiled and statistically analyzed using Chi-square test for categorical data; the intergroup comparison was analyzed using independent student's T-test. IBM SPSS Statistics 25 was used for statistical analysis. P < 0.05 was considered as significant.
RESULTS
All patients in Group B and T were male, ASA I and II, and all underwent inguinal hernia repair. Mean age in Group B and T was 40.35 ± 13.12 y and 40.16 ± 11.56 y respectively. The characteristics of subarachnoid block and observed side-effects between both groups are shown in Table 1 and Table 2 respectively. Table 3 shows duration of postop analgesia, total dose of rescue analgesia used within 24 h. Total dose used in 24 h is significantly reduced in Group T, but the duration of postop analgesia is not statistically significant among both groups.
VAS scores for 24 h postoperative period of both groups are shown in Table 3 . VAS scores were significantly low in Group T at 1.5, 2, 4, 8, 12, and 16 h. At 24 h it was comparable in both groups.
8 patients out of 55 in tramadol group and 4 patients out of 55 in buprenorphine group experienced hypotension; whereas, 10 patients in tramadol group and 8 patients in buprenorphine group complained of nausea. Incidence of shivering was more in buprenorphine groups. No adverse effects like pruritus, ECG changes, bradycardia or respiratory depression were encountered in either of the groups.
DISCUSSION
Tramadol and buprenorphine both have proven to be effective drugs for postop analgesia. In Pakistan currently only these two drugs are easily available for use as adjuvant in intrathecal space. However, no randomized control trial to compare their effectiveness in prolonging the duration of postopanalgesia, block characteristics and adverse effects has ever been conducted. 
original article
A study conducted in India in 2017 showed onset of sensory block to be 1.91 ± 0.438 min and onset of motor block to be 2.4 ± 0.572 min, when 20 mg tramadol was used with 15 mg of bupivacaine intrathecally. The results of demand for first rescue analgesia in this study are comparable to our results i.e. 324 ± 5.79 sec, but the onset of sensory and motor block was faster, probably due to higher dose of bupivacaine used. 8 Jamadar et al. found that duration of postop analgesia was prolonged to (317.14 ± 6.54 min) when 20 mg tramadol was added to 9 mg bupivacaine, which is consistent with our results. 11 A study by Chakrbarty et al. investigated tramadol, and found duration of effective analgesia to be 380 ± 11.82 min. He also studied VAS score in postop period. Similar to our findings, the VAS scores were remarkably reduced i.e. less than 4, 6 h postoperatively. 12 A study done in Karnatka in 2015 showed prolongation of effective postop analgesia till 232.18 ± 80.85 min, and time to achieve highest sensory block of 4.80 ± 1.09 min, when 10 mg of tramadol was used as an adjuvant with bupivacaine. This difference in results is most probably due to lower dose of tramadol being used. 13 Another study conducted in India in 2014 studied effects of adding 60 µg of buprenorphine with 15 mg of bupivacaine. Duration of postop analgesia was similar to our observation of 289.66 ± 64.94 min. 10 The variation is seen in onset of motor blockage that is faster probably due to higher dose of both drugs In our study VAS never rose above 2.95 and 2.20 in Group B and T respectively as 14 (25%) patients in Group B and 22 patients (40%) in Group T did not complain of pain and didn't receive any rescue analgesic, and there VAS did not rose above 2 in postoperative period. Because of those patients the overall VAS score of both groups is reduced, as VAS is calculated as mean of all patients of both groups.
Tramadol and buprenorphine both are semisynthetic opioids and are used as adjuvants for spinal anesthesia to prolong period of effective postop analgesia. Buprenorphine is 20 to 30-fold more potent than morphine , due to its high lipid solubility. 17 It has significantly strong binding at mu receptors and can nearly maximally occupy them, and due to its slower dissociation rate of 166 mins it cannot be easily displaced by full opioid agonists. 18 Tramadol, a centrally acting anodyne comprises of two enantiomers, both of which offer analgesia via different modes. (+)-tramadol and the metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the mu opioid receptor. (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake, enhancing inhibitory effects on pain transmission in the spinal cord. 19 This dual mechanism of action might explain the longer duration of postoperative analgesia and better VAS scoring in tramadol group in our study.
LIMITATIONS
Some limitations of our study were that we did not compare the changes in blood pressure among the two groups after intrathecal administration. Also, the mean age range was 42-44 years and older patients were not assessed. Future studies can be done to find any changes in hemodynamics and effects in elderly patients too.
CONCLUSION
Tramadol and buprenorphine are found to be effective adjuvants for prolonging postoperative analgesia, when added to intrathecal bupivacaline, but tramadol was associated with significantly reduced VAS scoring, prolonged duration of postop analgesia and reduced total dose of parenteral analgesics used in 24 h postoperatively without any significant difference in side effects. 
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